Fulcrum Therapeutics, Inc. Balance Sheet
FULC / Health Care|8 years of annual SEC 10-K data (FY2018-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 8 fiscal years. All figures from audited SEC 10-K filings.
Fulcrum Therapeutics, Inc. had $366M in total assets and $349M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 8.44 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $197.5M | $58.2M | $25.6M | $35.1M | $35.4M | $57.1M | $96.7M | $72.8M |
| Current Assets | $357.5M | $249.9M | $242.2M | $207.5M | $226.0M | $119.5M | $100.1M | $74.1M |
| PP&E (Net) | $2.8M | $3.9M | $5.2M | $6.9M | $7.4M | $8.4M | $9.2M | $10.5M |
| Total Assets | $366.3M | $260.7M | $257.7M | $226.7M | $235.0M | $129.6M | $110.4M | $85.8M |
| Current Liabilities | $13.0M | $11.0M | $13.7M | $16.7M | $19.2M | $26.7M | $12.1M | $4.2M |
| Shareholders' Equity | $349.0M | $243.0M | $235.2M | $198.9M | $211.5M | $95.2M | $87.2M | -$63.7M |